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Summary Numerous interactions between malignant and stromal/inflammatory cells take place within solid
human tumours, which are mediated, in part, by the release of signalling proteins called cytokines. In the
present study, we have compared the secretion of two important immunomodulatory cytokines, IFN-y and
IL-4 by individual, immunophenotyped NK cells freshly isolated from either malignant tumour biopsies, or
peripheral blood samples from patients with ductal invasive breast cancer. Due to the marked heterogeneity
amongst cells isolated from these clinical samples, we have employed a technique called the reverse haemolytic
plaque assay to identify and enumerate cytokine-secreting cells at the single cell level. Our data indicate that
NK cells isolated directly from the tumour site secrete more IFN-y and IL4 than NK cells from the blood of
the same patients. However, a greater proportion of CD16+ cells from both sources in breast cancer patients
secreted IFN-y than of those from the blood of healthy donors. We also show that factors secreted by the
human breast cell lines, MCF-7 and MDA-231 PN9, were able to mimic the stimulatory influence of the
tumour microenvironment on secretory activity of NK cells.
Natural killer (NK) cells can be defined on the basis of their
ability to lyse certain tumour cells in a manner which is not
dependent upon the expression of MHC molecules. In man,
such 'natural' cytotoxicity is displayed mainly by CD3/
CD16+ cells with the morphology of large granular lympho-
cytes (LGL) (Timonene et al., 1981; Ortaldo et al., 1986;
Lanier et al., 1986). NK cells can also be stimulated by IL-2
or IFN-y to express a broader range of cytotoxicity, known
as lymphokine activated killer (LAK) activity. Their ability
to lyse tumour cells in vitro has led to the experimental use of
NK and LAK cells in the immunotherapy of some types of
human cancer. This has occasionally led to tumour regres-
sion and/or improved clinical prognosis in advanced renal
cell cancers and melanomas (Lotze et al., 1986; Mule et al.,
1986).
However, there is also evidence to suggest that the cytotox-
icity of NK cells towards tumour cells may actually be
markedly reduced once they infiltrate the microenvironment
of a malignant tumour (Moy et al., 1985; Lotzova, 1988;
Nakamura et al., 1988). Indeed, malignant tissues release
factors which suppress various immune functions in draining
lymph nodes (Wen et al., 1989), and cultured tumour cells
have been shown to inhibit the generation of LAK cells in
vitro (Guillou et al., 1989). That factors produced by the
malignant cell population itself may mediate, at least in part,
this immunosuppression is given credance by the finding that
factors known to be produced by human cancer cells, such as
TGF-I or prostaglandin E2, markedly inhibit the cytotoxicity
of NK and LAK cells in vitro (Rook et al., 1986; Wahl et al.,
1988; Leung, 1989; Luger et al., 1989).
NK cells secrete a range of cytokines, including IFN-y,
IL-2, (Djeu et al., 1982) and TNF-a (Peters et al., 1986)
which are capable of directly lysing neoplastic cells in a time
dependent manner (Uchida et al., 1985; Ruggerio et al.,
1987). Recently, interleukins 4 and 6, which are also NK cell
products (Tamm et al., 1989) have been shown to alter the
proliferation and metastatic potential of malignant cells in
vitro (Pusztai et al., 1991). Taken together, these findings
suggest that NK cells may contribute a number of cytokines
to the complex cytokine network which exists within the
microenvironment of solid human tumours (Lewis, 1991), and
which collectively regulates the activity of both resident
neoplastic cells and immune cells infiltrating such tissues.
A sensitive immunoassay called the reverse haemolytic pla-
que assay (RHPA) has recently been introduced for the
measurement of cytokine secretion by individual, immuno-
identified human cells (Lewis et al., 1990). In the present
report, the RHPA has been used to investigate the influence
of the tumour microenvironment on the release of IFN-- and
IL-4 by individual human CD16+ NK cells. To do this, the
secretory activity of NK cells derived from both tumour and
the peripheral blood samples of patients with ductal invasive
breast carcinoma were compared. In addition, experiments
were undertaken to investigate the effects of soluble media-
tors released by the breast adenocarcinoma cell lines, MCF-7
and MDA-231 PN9, on the secretion of cytokines by NK
cells in vitro.
Materials and methods
Isolation ofmononuclear cellsfrom theperipheral bloodof
cancerpatients
Peripheral blood samples (10 ml) were obtained from patients
undergoing mastectomy (prior to surgery). Peripheral blood
mononuclear cells (PBMC) were isolated using Ficoll-Hy-
paque density gradients. Briefly, this involved diluting whole
blood samples 1: 1 (v/v) in calcium and magnesium-free
Hank's buffered salt solution (HBSS). The resultant cell
suspensions were then washed three times before being care-
fully layered onto Ficoll-Hypaque cushions. After centrifuga-
tion for 25 min at 450 g, cells in the lymphocyte layer were
collected and washed by centrifugation/resuspension three
times in HBSS. This procedure routinely yielded 1-5 x 106
cells ml-'.
Enrichment ofNK cellsfrom theperipheral blood ofhealthy
donors
Human NK cells were isolated from 1,000 ml buffy coat
preparations from five healthy female donors. PBMC were
isolated using Ficoll-Hypaque density gradients as outlined
above. The resulting cell pellet was resuspended in complete
culture medium (see below) and incubated in large plastic
culture dishes for 60 min at 37C to remove plastic-adherent
monocytes. Non-adherent cells were harvested and then
incubated in nylon wool columns for 30 min at 37°C to
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remove B cells (Julius et al., 1973). T cells were removed by
the negative panning technique (Garcia-Penarrubia & Bank-
hurst, 1989). Briefly, this involved incubating cells (5 x 106
cellsml-') with monoclonal antibodies (10tIml-1) specific
for the CD3, CD4 and CD8 surface antigens on T cells
(Dako, High Wycombe, UK) for 30min at 4°C. The cell
suspension was then layered onto polystyrene Petri dishes
(Sterilin, UK), previously coated with goat anti-mouse IgG,
for 60 min at 4°C. Non-adherent lymphoid cells (i.e. mainly
NK cells) were carefully aspirated from each dish and used
for subsequent experiments.
Unfortunately, experiments using breast cancer patient's
PBMC enriched for NK cells could not be performed as the
negative panning procedure requires 500-1,000 ml of whole
blood. For obvious clinical reasons, the removal of this
quantity of blood from each breast cancer patient was not
feasible.
Enzymatic dispersion ofcells in malignant breast biopsies
Mastectomy resections for breast cancer were collected im-
mediately after surgery. Each tumour was dissected out and a
portion removed for histopathological diagnosis. At the same
time, a small (1 cm3) piece of tissue containing tumour was
also removed and digested with 0.1% collagenase type IV
(Sigma, Dorset, UK) in RPMI 1640 medium for 2 h at 22°C.
Enzymatically dispersed cells were removed, suspended in
10 ml of HBSS and centrifuged at 444 g for 15 min. The
supernatant was discarded and this step repeated four times
in order to remove contaminating enzyme. This procedure
routinely yielded 1-20 x 106 cells ml1'. Monocytes were re-
moved by adherence to plastic culture wells during a 60 min
incubation. As a control, peripheral blood mononuclear cells
from each of the cancer patients were subjected to similar
collagenase treatment for 2 h and their secretory activity
assessed in the RHPA.
Culture conditions andpreparation oftumour cell supernatants
Cultures of MCF-7 or MDA-231-PN-9 cells were maintained
in RPMI 1640 medium supplemented with 2 mm of gluta-
mine, 10% foetal calf serum, 1OOIU ml-' penicillin G and
100 ug ml1' streptomycin (complete culture medium) at 37'C
in air/5% CO2. All culture reagents used were obtained from
Gibco, Paisley, UK. The human breast cancer cell lines,
MCF-7 and MDA-231 PN-9, were propagated in complete
culture to medium to near (>90%) confluence. Cells were
incubated with fresh medium for 24 h and the medium then
removed and centrifuged at 5,000 g for 20 min. The super-
natant was filtered (pore size 0.2 jAm) and used immediately
as conditioned medium in subsequent medium-transfer exper-
iments. Small aliquots of each batch of conditioned medium
were transferred to glass slides and stained with haemotoxylin/
eosin to check for the absence of any contaminating tumour
cells.
Reverse haemolytic plaque assay
The secretion of IFN-y and IL-4 was measured using the
RHPA as previously described for cytokines (Lewis et al.,
1990). Mononuclear human cells were suspended in RPMI
1640 medium supplemented with 0.1% bovine serum albu-
min, 2 mM glutamine and antibiotics (assay medium) and
then mixed with ovine red blood cells (Serotec, Kidlington,
UK) to which staphylococcal protein A (Sigma Chemicals,
Dorset, UK) had been coupled using the chromium chloride
method. This cell suspension was allowed to settle in Cun-
ningham chambers for 45 min at 37°C in air/5% CO2. Non-
attached cells were removed with prewarmed assay medium
and the chambers filled with a 1:50 dilution of polyclonal
rabbit antisera to either native human IFN-' or recombinant
human IL-4 (Genzyme, USA). After incubation for 6 h, pla-
que formation was induced by infusion into the chambers of
a 1:50 dilution of guinea pig complement in assay medium.
The cell monolayers were then fixed with 2% glutaraldehyde
(v/v) in phosphate buffered saline and stored at 4'C for
subsequent analysis. All treatments were repeated on 10
separate slides in each assay.
Immunocytochemistry
Mononuclear cells were phenotyped by immunocytochemis-
try with monoclonal antibodies against CD3, CD4, CD8
(Dako, UK) and CD16 antigens (Becton Dickinson, UK).
Slides were incubated with the monoclonal antibodies in
Tris-buffered saline (TBS) with 5% low fat milk protein
('Marvel', Premier Brands, Birmingham, UK) at optimal
dilutions for 4 h at 22°C. After several washes in TBS, bound
antibodies were detected by the APAAP technique (Cordell
et al., 1984) using fast red as chromogen. Nuclei were lightly
counterstained with haematoxylin.
Morphometry and statistics
The area ofthe plaques formed in the RHPA was determined
using a WILD M-20 microscope to which a drawing device
had been attached. This allowed the superimposition of the
microscopic image onto the screen of an Apple Macintosh
computer. Plaques were traced manually with a cursor and
areas calculated by a program developed by Dr J. Lorenzen
in this Department. For IFN-y secretion, the size of the first
20 randomly selected haemolytic plaques was measured on
each of 5-10 replicate slides for each treatment (i.e.
minimum of 100 plaques). For IL-4 secretion, all plaques on
replicate slides were measured (as there was invariably fewer
of the latter). To rule out subjective bias, all plaque sampling
was performed 'blind' without prior knowledge of the source
of NK cells. Statistical analysis of the data was performed
using the Mann-Whitney U test. Although data from single,
representative experiments have been illustrated in this
report, essentially similar results were obtained in five iden-
tical assays using blood or tumour samples from at least five
separate individuals.
Results
Immunocytochemical labelling ofcellpreparations used in the
RHPA
Table I indicates the higher proportions of cells expressing T
(CD3, CD4 and CD8) and NK cell (CD16) antigens in
PBMC isolated from breast cancer patients (after Ficoll-
hypaque purification) than in cell preparations directly iso-
lated from enzymatically-dispersed breast tumours. However,
a slightly higher frequency of CD16+ cells were seen in
dispersed tumour-associated mononuclear cells.
Negative panning of PBMC from healthy donors re-
producibly enriched the proportion of CD16+ cells to >65%,
and depleted cells bearing the CD3, CD4 and CD8 antigens
to <5% (data not shown). Fifteen to twenty per cent of
CD16+ NK cells from healthy donors enriched in this way
secreted IFN-'y, whereas fewer than 2% of CD3+ or CD4+
cells secreted this cytokine in the RHPA (Table II). By
Table I Frequency of cells bearing various CD antigens in cell
preparations used in the RHPA
Tumour-associated





Peripheral blood mononuclear cells (PBMC) were isolated from the
peripheral blood of a breast cancer patient using a Ficoll-Hypaque
gradient. Tumour-associated mononuclear cells were isolated by
enzymatic dispersion of the malignant breast biopsy from the same
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contrast, only a small subpopulation (i.e. 1-2%) of the total
number of enriched CD16+ NK cells present secreted IL-4
(data not shown). However, over 30% of CD16+ cells
derived from either the blood or tumours of breast cancer
patients secreted IFN-y (Table II). A higher proportion of
CD4+ cells isolated from breast tumours (i.e. 20%) was
found to release IFN-y than those isolated from the peri-
pheral blood (i.e. 3%) of the same patients (Table II).
To determine the identity of the main producer cell type(s)
for IFN-y and IL-4 in the various cell preparations used in
these studies, the proportion of the total plaque-forming cells
bearing each of the CD antigens was calculated. The maj-
ority (i.e. 80-90%) of cells secreting these cytokines in the
RHPA were seen to be CD3 or CD16+, irrespective of
whether they were derived from healthy donors or patients
with breast malignancies (data not shown).
Comparison ofthe secretory activity ofNK cells derivedfrom
theperipheral blood or tumours ofbreast cancerpatients
Figure 1 illustrates the appearance of a haemolytic plaque
formed by an NK cell secreting IFN-y. The secretory cell is
surrounded by an area of erythrocyte ghosts (plaque). Tu-
mour-associated NK cells released significantly (P<0.01)
more IFN-y and IL-4 than those from the peripheral blood
of the same patients (Figure 2). This difference was not due
to the collagenase treatment of tumour-associated NK cells,
as incubation of peripheral blood NK cells with collagenase
for 2 h did not result in alterations in cytokine release (data
not shown).
It should be noted that IFN-' secretion was consistently
detected in every blood and biopsy sample. By contrast, the
release of IL-4 was only detected in blood samples from 50%
Figure 1 Light micrograph of a haemolytic plaque formed by an
NK cell secreting IFN-y in the RHPA. Human cells were isolated
and mixed with SpA-coated ovine red blood cells coated with
protein A. These cells were incubated as a monolayer with poly-
clonal antiserum against human IFN-y in for 6 h. Plaque forma-
tion was induced by the addition of guinea pig complement.
(Magnification bar = 50;Lm).
(6/12) of the healthy donors and 10% (2/20) of the cancer
patients tested.
Effect ofmedium conditioned by breast cancer lines on the
secretory activity ofNK cells
For these experiments, NK cell enriched populations of
PBMC were used (see above). Figure 3 illustrates the
significant (P<0.01) stimulation of IFN-7 and IL-4 secretion
by CD16+ NK cells derived from healthy donors after
exposure to medium conditioned by MCF-7 cells. Exposure
to conditioned medium did not alter the proportion of
CD16+ or CD4+ cells secreting IFN-y in the RHPA (data
not shown). Essentially similar results were obtained using
medium conditioned by MDA-231 PN9 cells (data not
shown).
Discussion
Any investigation of the activity and regulation of neoplastic
cells in solid human tumours is complicated by the presence
of considerable numbers of infiltrating stromal/immune cells
at the tumour site. Macrophages alone, for example, can
comprise over 50% of the total cell number in malignant
breast tumours (Kelly et al., 1988).
In the present report we have employed a technique which
permits the detection of cytokine secretion at the single cell
level to investigate the cytokine communication which occurs
in malignant tissues between resident malignant cells and NK
cells. Since the area of haemolysis surrounding a secreting
cell in the RHPA has been shown to be directly proportional
to the amount of product secreted (Neill et al., 1987), this
technique allows the quantitation of cytokine secretion by
individual cells and its modulation by various stimuli. The
coupling of the RHPA with immunocytochemistry to pheno-
type producer cells allows the contributions made by various
cell types to the overall level of secretion of a given cytokine
to be assessed.
Cytokine levels in the serum can vary between individuals,
but are usually a stable individual property (Moelvig et al.,
1988). For this reason, we chose to compare the cytokine-
secreting activity of tumour-infiltrating NK cells with those
from the blood of the same patients. Our studies indicate
that CD16+ NK cells are the main source of IFN-y spontan-
eously secreted in short-term cultures of human PBMC or
dispersed malignant breast tumours. This correlates well with
the finding that it is NK cells, rather than T cells, which are
the major producer cells for IFN-'y in vitro in the absence of
exogenous stimulation (Young & Ortaldo, 1987).
That NK cells secrete IL-4, as well as IFN-7 and IL-2, was
inferred in the early report of Procopio and coworkers
(1985). Our studies using the RHPA have both provided
unequivocal evidence of IL-4 secretion by CD16+ NK cells,
and revealed a marked heterogeneity amongst NK cells in
their ability to secrete IFN-y or IL-4. However, without the
application of either a variant of the RHPA called the
'sequential' RHPA, to visualise the secretion of both these
cytokines by the same cells (Neill et al., 1987), or their dual
labelling by immunofluorescence (Anderson et al., 1990), it is
not possible to say whether the 1% of CD16+ cells which










Figure 2 Comparison of the mean ( ± s.e.m.) size of IFN-y and
IL-4 plaques formed by NK cells derived from either the
peripheral blood (open bars) or breast tumour (opaque bars) of
the same patient. The identity of plaque-forming cells as predom-
inantly CD16+ NK cells was confirmed by immunocytochemis-








Figure 3 Effect of medium conditioned by MCF-7 cells on the
mean (± s.e.m.) size of IFN-y or IL-4 plaques formed by human
CD16+ NK cells derived from the peripheral blood of healthy
female donors. PBMC which had been enriched for NK cells
were incubated for 24 h with incubation medium alone ('control
group'; open bars) or medium conditioned by the breast cancer
cell line, MCF-7 (shaded bars), prior to their use in the RHPA.
*P<0.01 compared to respective control group.
exists that cells secreting each of these products may have
represented functionally distinct subpopulations of NK cells.
Although the reason(s) for the greater frequency of NK cells
secreting IFN-' than IL-4 remains unclear, this finding ac-
cords well with recent reports showing the differential prod-
uction of IFN-y and IL-4 by stimulated human T cells in
vitro (Lewis et al., 1988; Anderson et al., 1990).
This study is the first to demonstrate an augmented secre-
tion of IFN-y and IL-4 by tumour-associated CD3-/CD16+
NK cells. The finding that NK cells secrete greater quantities
of IFN-' once they reach a malignant tissue is not surprising
in view of the finding that LAK cells secrete elevated levels of
IFN-y and TNF-x when coincubated with tumour cells
(Chong et al., 1989). The medium transfer experiments con-
ducted in the present study also indicate that factors secreted
by tumour cells in culture, may be involved in the activation
of NK cell secretory activity by the microenvironment of the
tumour.
IL-4 has been shown to inhibit IFN-y production in
mononuclear cells (Peleman et al., 1989). Our finding that
both IL-4 and IFN-y levels were elevated in human breast
tumours suggests that, at least for a proportion of the
tumour-associated NK cell population, this negative feed-
back loop may not be operative. The increased secretion of
these two cytokines by NK cells within the tumour may have
numerous implications for both tumour progression and the
regulation of cell-mediated cytotoxicity against tumour cells.
It is likely that they are two, amongst many cytokines which
have been implicated as mediators of the intercellular com-
munication which takes place within malignant tumours.
Indeed, these often act back on the producer cell itself in an
autocrine fashion (for review, see Lewis, 1991). Both cyto-
kines stimulate the secretory activity of human NK cells in
vitro (Lewis et al., 1991) and can modulate the induction of
LAK cell activity (Mule et al., 1987; Widmer et al., 1987;
Giovarelli et al., 1988). Within the tumour, IL-4 can act on
other non-malignant cells either synergistically or antagonis-
tically with IFN-'y. This is best illustrated in the case of
macrophages, where IL-4 can be regarded mainly as the
functional antagonist of IFN-y. Whereas both cytokines in-
crease the expression of MHC class II antigens by macro-
phages (Crawford et al., 1987), IL-4 also acts to reduce their
tumouricidal activity (te Velde et al., 1988; Hart et al., 1989).
It is also known to inhibit macrophage activation by IFN-y
(Lehn et al., 1989). The differential effects of IL-4 on NK cell
activity and inhibition of macrophage cytotoxicity make it
difficult to predict the overall effect of increased IL-4 levels
for the tumour-bearing host. However, in transgenic mice
producing high levels of IL-4, there is evidence for reduced
tumour growth (Tepper et al., 1989).
The role of IL-4 receptors which have been shown to be
expressed on neoplastic epithelial cells and fibroblasts (Al
Jabari et al., 1989) has yet to be established, but raises the
possibility that IL-4 is able to modulate tumour cell function
directly. In the case of IFN-y, Jabrane-Ferrat and coworkers
(1990) have shown that this cytokine protects human breast
cancer cells from NK and LAK cell lysis. However, such an
effect might be specific to malignant breast cells, as this
interferon is reported to increase in susceptibility of a neuro-
blastoma cell line to cell-mediate cytotoxicity (Handgretinger
et al., 1989). In addition, our own recent studies have
indicated a role for IFN-y and IL-4 in regulating the growth
of breast cancer cell lines in vitro (Pusztai et al., 1991).
The cellular mechanism(s), by which tumour cells might
play a part in stimulating the secretion of IL-4 and IFN-y by
NK cells remain(s) to be identified. The possibility exists that
the elevated level of cytokine released by tumour-associated
NK cells reported here may have resulted, not so much from
their exposure to activating factors produced within the
tumour, but rather their release from local inhibitory influ-
ences. However, this seems unlikely since we have also dem-
onstrated that medium conditioned by breast cancer cell lines
stimulates, rather than inhibits, cytokine secretion by human
NK cells in vitro. Cytokines may be secreted by neoplastic
cells which directly modify the secretory activity of NK cells.
Indeed, we have recently shown that one putative tumour cell
product, namely basic form of fibroblast growth factor
markedly enhances the secretion of IFN-y by human CD16+
NK cells in vitro (Lewis et al., 1991). It is, therefore, possible
that this and/or other cytokines secreted by the neoplastic
cell population may play a part in the stimulation of NK cell
secretory activity at the tumour site. They may also play a
part in the mitogenic stimulation of lymphocytes by tumour
cell lines recently reported by Packard (1990).
Taken together, the studies outlined in this report demon-
strate that soluble, tumour-specific signals augment the secre-
tion of IFN-y and IL-4 by human CD16+ NK cells, and that
the neoplastic cell population is one potential source of such
stimulatory factors.IFN-T/IL4 RELEASE AND TUMOUR NK CELLS 461
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